Importance of TURP in diagnosing prostate cancer in men with multiple negative biopsies

Prostate

Volumn 64, Issue 2, 2005, Pages 200-202

  Philip, J ^a,b,c   Roy, S Dutta ^b   Scally, J ^b   Foster, C S ^a   Javle P ^b  

^a ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

^b LEIGHTON HOSPITAL   (United Kingdom)

^c NONE   (United Kingdom)

Author keywords

12 core biopsy; Prostate cancer; Radical prostatectomy; Transurethral resection

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER INVASION; CANCER SURGERY; CLINICAL ARTICLE; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; TRANSRECTAL ULTRASONOGRAPHY; TRANSURETHRAL RESECTION;

AGED; BIOPSY, NEEDLE; HUMANS; MALE; MIDDLE AGED; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TRANSURETHRAL RESECTION OF PROSTATE; TREATMENT OUTCOME;

EID: 20344382972     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.20239     Document Type: Article

References (23)

1. Cancer research UK, 2004. "Statistics-Prostate cancer" last updated 09/02/2004. URL: http://www.cancerresearchuk.org/aboutcancer/statistics/ prostate.cancer Date of access: 08/07/ 2004.
2. Hsing AW, Tsao L, Devesa S. International trends and patterns of prostate cancer incidence and mortality. Int J Cancer 2000;85(1): 60-67.
3. Ito K, Yamamoto T, Ohi M, Kurokawa K, Suzuki K, Yamanaka H. Free/total PSA ratio is a powerful predictor of future prostate cancer morbidity in men with initial PSA levels of 4.1 to 10.0 ng/ ml. Urology 2003;61(4):760-764.
4. Partin AW, Brawer MK, Subong EN, Kelley CA, Cox JL, Bruzek DJ, Pannek J, Meyer GE, Chan DW. Prospective evaluation of percent free-PSA and complexed-PSA for early detection of prostate cancer. Prostate Cancer Prostatic Dis 1998;1(4):197-203.
5. Oremek GM, Sapoutzis N, Eden F, Jonas D. Complexed PSA in routine diagnosis. Anticancer Res 2003;23(2A):975-977.
6. Riffenburgh RH, Amling CL. Use of early PSA velocity to predict eventual abnormal PSA values in men at risk for prostate cancer. Prostate Cancer Prostatic Dis 2003;6(1):39-44.
7. Lujan M, Paez A, Llanes L, Miravalles E, Berenguer A. Prostate specific antigen density. Is there a role for this parameter when screening for prostate cancer? Prostate Cancer Prostatic Dis 2001;4(3):146-149.
8. Ozen H, Aygun C, Ergen A, Sozen S, Aki FT, Uygur MC. Combined use of prostate-specific antigen derivatives decreases the number of unnecessary biopsies to detect prostate cancer. Am J Clin Oncol 2001;24(6):610-613.
9. Rabbani F, Stroumbakis N, Kava BR, Cookson MS, Fair WR. Incidence and clinical significance of false-negative sextant prostate biopsies. J Urol 1998;159(4):1247-1250.
10. Epstein JI, Walsh PC, Sauvageot J, Carter HB. Use of repeat sextant and transition zone biopsies for assessing extent of prostate cancer. J Urol 1997;158(5):1886-1890.
11. Stroumbakis N, Cookson MS, Reuter VE, Fair WR. Clinical significance of repeat sextant biopsies in prostate cancer patients. Urology 1997;49(3A Suppl):113-118.
12. Norberg M, Egevad L, Holmberg L, Sparen P, Norlen BJ, Busch C. The sextant protocol for ultrasound-guided core biopsy cores of the prostate under-estimates the presence of cancer. Urology 1997;50(4):562-566.
13. Eskew LA, Bare RL, McCullough DL. Systematic 5 region prostate biopsy is superior to sextant method for diagnosing carcinoma of the prostate. J Urol 1997;157(1):199-203.
14. Levine MA, Ittman M, Melamed J, Lepor H. Two consecutive sets of transrectal ultrasound guided sextant biopsies of the prostate for the detection of prostate cancer. J Urol 1998;159(2): 471-475.
15. McNeal JE. Origin and development of carcinoma in the prostate. Cancer 1969;23(1):24-34.
16. Garber SJ, Goldenberg SL, Cooperberg PL, Wong AD, Bilby JH, Mathieson JP. Systematic transrectal ultrasound-guided biopsy of the prostate. Can Assoc Rad J 1994;45(5):387-390.
17. Philip J, DeSouza J, Hough C, Javlé P. Role of peripheral basal biopsies in prostate cancer detection. Br J Urol Int 2003; 91(s2):49.
18. Vanasupa BP, Miller TA, Schwartz BF. Diagnosis of prostate adenocarcinoma using transurethral resection of the prostate after multiple negative transrectal biopsies and persistently elevated prostate-specific antigen level. Urology 2000;56(6): 1056xi-1056xii.
19. Niesel T, Breul J, Hartung R. Diagnostic value of additional systematic prostate biopsies in patients undergoing transurethral resection of the prostate. Urology 1997;49(6):869-874.
20. Ornstein DK, Rao GS, Smith DS, Andriole GL. The impact of systematic prostate biopsy on prostate cancer incidence in men with symptomatic benign prostatic hyperplasia undergoing transurethral resection of the prostate. J Urol 1997;157(3):880-884.
21. Ito H, Yamaguchi K, Kotake T, Matsuzaki O, Nagao K. Usefulness of aspiration cytology in prostate cancer detection. Int Urol Nephrol 1995;27(1):93-100.
22. Kitamura H, Masumori N, Tanuma Y, Yanase M, Itoh N, Takahashi A, Tsukamoto T, Adachi H, Hotta H. Does tansurethral resection of the prostate facilitate detection of clinically significant prostate cancer that is missed with systematic sextant and transition zone biopsies? Int J Urol 2002;9(2):95-99.
23. Rovner ES, Schanne FJ, Malkowicz B, Wein AJ. Transurethral biopsy of the prostate for persistently elevated or increasing prostate specific antigen following multiple negative transrectal biopsies. J Urol 1997;158:138-142.